Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

NEW YORK , June 16, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Outset Medical, Inc. (NASDAQ :OM) resulting from allegations that Outset may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Outset securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Outset Medical, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - OM

Los Angeles, California--(Newsfile Corp. - June 15, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Outset provided guidance for the second quarter of 2022 as part...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Outset Medical, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Outset investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) investors concerning the Company's possible violations of federal securities laws. On June 13, 2022, after the market closed, Outset announced that it had implemented “a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending” a review and clearance of a 510(k) application by the U.S. Food and Drug Ad

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

The temporary issue could present a great buying opportunity for long-term investors.

Outset Medical Plunges on Shipment Hold: Buy the Stock on the Sell-Off?

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 13, 2022, after the market closed, Outset announced that it had implemented “a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending”

The Law Offices of Frank R. Cruz Announces Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM) resulting from allegations that Outset may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Outset securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th

OM INVESTOR NOTICE: Rosen Law Firm Encourages Outset Medical, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – OM

Outset Medical Inc (NASDAQ: OM) implemented a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending the FDA review and clearance of a 510(k). The company submitted for changes made since the device's original March 2020 clearance.

Why Outset Medical Shares Are Trading Lower Today

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “company”) today announced it has implemented a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending the Food and Drug Administration's (FDA) review and clearance of a 510(k) the company submitted for changes made since the device's original March 2020 clearance. Outset has not identified any safety issues with Tablo. The company will continue to market and ship Tablo for use

Outset Medical Announces Shipment Hold on New Tablo Systems for Home Use Pending FDA Review and Clearance of Recent 510(K) Submission

Fulgent Genetics

These companies have low share prices and high potential.

2 No-Brainer Stocks to Buy Right Now for Less than $55

Outset Medical, Inc. (NASDAQ:OM ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Leslie Trigg – Chair and Chief Executive Officer Jim Mazzola – Head of Investor Relations Nabeel Ahmed – Chief Financial Officers Conference Call Participants Philip Coover – Goldman Sachs Rick Wise – Stifle Travis Steed – Bank of America Suraj Kalia – Oppenheimer Josh Jennings – Cowen Danielle Antalffy – SVB Securities Drew Ranieri – Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Outset Medical First Quarter 2022 Earnings Conference Call.

Outset Medical, Inc. (OM) CEO Leslie Trigg on Q1 2022 Results - Earnings Call Transcript

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Recorded net revenue of $30.6 million in the first quarter of 2022, a 33.3% increase compared to $22.9 million in the first quarter of 2021 and an 8.5% increase compared to $28.2 million i

Outset Medical Reports First Quarter 2022 Financial Results

Aurinia Pharmaceuticals

Shockwave Medical

Here's why three Fool.com contributors are bullish on Outset Medical, Aurinia Pharmaceuticals, and Shockwave Medical.

3 Healthcare Companies With Revenue Spiking 100% or More

Outset Medical, Inc. (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Outset Medical, Inc. (OM) to Report a Decline in Earnings: What to Look Out for

This company helps keep patients at home with dialysis treatments.

Why I'm Over the Moon for This Healthcare Stock -- In One Chart

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 12:00pm PT / 3:00pm ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the Outset website at https://investors.outse

Outset Medical to Present at the BofA Securities 2022 Healthcare Conference

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. “Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team,” said Chair and CEO Leslie Trigg. “He leads with purpose and deeply understands the role values and culture play in building hi

Outset Medical Names Business Leader Dale E. Jones to Board of Directors

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a con

Outset Medical to Report First Quarter 2022 Financial Results on Wednesday, May 4, 2022

These two companies are leading the charge for improved patient outcomes.

2 Medtech Stocks You Can Buy and Hold for the Next Decade

Affimed

Inmode Ltd

Finding stocks with significant upside before the rest of the market sees what's happening can be highly profitable.

3 Under-the-Radar Biotech Stocks That Will Zoom Higher

SAN JOSE, Calif.--(BUSINESS WIRE)-- #betterbeginsnow--Outset Medical Presents New Data on Home Dialysis at National Kidney Foundation Spring Meetings

Outset Medical Presents New Data on Home Dialysis at National Kidney Foundation Spring Meetings

Chevron

Devon Energy

Imperial Petroleum

Camber Energy

Indonesia Energy Corp Ltd

Oil stocks are lower today on reports that the White House plans to release a record amount of oil onto the market. The post Oil Stocks News: Why Are XOM, DVN, INDO, IMPP, CEI, CVX Stocks in the Spotlight Today?

Oil Stocks News: Why Are XOM, DVN, INDO, IMPP, CEI, CVX Stocks in the Spotlight Today?

Doximity

Pieris Pharma

Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.

3 Biotechs That Will Crush the Bear

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference on Tuesday, March 8, 2022 at 11:50am PT / 2:50pm ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the Outset website at h

Outset Medical to Present at 42nd Annual Cowen Health Care Conference

Global-e Online Ltd

Find out why they're bucking the downtrend.

News for Outset Medical Stock (OM)